Breast cancer, characterized by hormone receptors, specifically, exhibits a decreased incidence of pathological complete response (pCR) in comparison to breast cancer with human epidermal growth factor receptor 2 (HER2+) and triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.